Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant

Phase 1

Completed

Conditions: Follicular Lymphoma
Mantle Cell Lymphoma
CD20 Positive
Chronic Lymphocytic Leukemia
Marginal Zone Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
T-Cell Non-Hodgkin Lymphoma

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Biological: Anti-Thymocyte Globulin
Drug: Bendamustine
Biological: Filgrastim
Drug: Fludarabine
Drug: Methotrexate
Biological: Rituximab
Drug: Tacrolimus

First Posted Date: 2009-04-14

Last Posted Date: 2019-06-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 60

Registration Number: NCT00880815

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory High-Risk NBL.

Phase 2

Withdrawn

Conditions: Neuroblastoma

First Posted Date: 2009-04-02

Last Posted Date: 2015-10-16

Lead Sponsor: Nationwide Children's Hospital

Registration Number: NCT00874315

Locations: 🇺🇸
Children's Memorial Hospital, Chicago, Illinois, United States
🇺🇸
Children's Hopsital of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸
Morgan Stanley Children's Hospital of NY, New York, New York, United States

and more 1 locations

Chemotherapy, Total-Body Irradiation, Donor Natural Killer Cell Infusion, Aldesleukin, and UCB Transplant in Treating Patients With Relapsed or Refractory AML

Phase 2

Terminated

Conditions: Leukemia

Interventions: Biological: aldesleukin
Drug: cyclophosphamide
Drug: fludarabine phosphate
Procedure: umbilical cord blood transplantation
Radiation: total-body irradiation

First Posted Date: 2009-03-30

Last Posted Date: 2017-12-28

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 2

Registration Number: NCT00871689

Locations: 🇺🇸
University of Minnesota Children's Hospital - Fairview, Minneapolis, Minnesota, United States

Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia

Phase 2

Completed

Conditions: Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Childhood Chronic Myelogenous Leukemia
Accelerated Phase Chronic Myelogenous Leukemia
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Lymphoblastic Leukemia in Remission
Adult Acute Myeloid Leukemia in Remission
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Childhood Acute Lymphoblastic Leukemia in Remission
Childhood Myelodysplastic Syndromes

Interventions: Drug: treosulfan
Drug: fludarabine phosphate
Radiation: total-body irradiation
Procedure: peripheral blood stem cell transplantation
Drug: tacrolimus
Procedure: allogeneic bone marrow transplantation
Procedure: allogeneic hematopoietic stem cell transplantation
Drug: methotrexate

First Posted Date: 2009-03-12

Last Posted Date: 2021-06-22

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 96

Registration Number: NCT00860574

Locations: 🇺🇸
University of Colorado, Denver, Colorado, United States
🇺🇸
Oregon Health and Science University, Portland, Oregon, United States
🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Lenalidomide Following Fludarabine/Rituximab (FR) in Untreated Chronic Lymphocytic Leukemia (CLL)

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Rituximab
Drug: Fludarabine
Drug: Lenalidomide

First Posted Date: 2009-03-12

Last Posted Date: 2018-11-21

Lead Sponsor: Georgetown University

Target Recruit Count: 22

Registration Number: NCT00860457

Locations: 🇺🇸
Lombardi Cancer Center at Georgetown University Medical Center, Washington, District of Columbia, United States

Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders

Not Applicable

Completed

Conditions: Accelerated Phase Chronic Myelogenous Leukemia
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
Adult Acute Myeloid Leukemia in Remission
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Angioimmunoblastic T-cell Lymphoma
Childhood Myelodysplastic Syndromes
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Childhood Diffuse Large Cell Lymphoma
Childhood Nasal Type Extranodal NK/T-cell Lymphoma

Interventions: Drug: fludarabine phosphate
Drug: melphalan
Radiation: total-body irradiation
Procedure: allogeneic hematopoietic stem cell transplantation
Biological: anti-thymocyte globulin

First Posted Date: 2009-03-05

Last Posted Date: 2019-11-13

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 62

Registration Number: NCT00856388

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab

Phase 2

Terminated

Conditions: Follicular Lymphoma

Interventions: Drug: fludarabine
Drug: VELCADE
Drug: rituximab

First Posted Date: 2009-02-25

Last Posted Date: 2012-12-12

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 12

Registration Number: NCT00850499

Locations: 🇬🇷
Laiko Hospital - 1st Dept. of Propaedeutic Internal Medicine, Athens, Greece
🇮🇱
Sheba MC - Hematology Institute, Ramat Gan, Israel
🇮🇱
Hadassah University Hospital - Hematology Department, Jerusalem, Israel

and more 40 locations

Fludarabine Phosphate, Rituximab, and Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Relapsed or Not Responded To Treatment

Phase 2

Withdrawn

Conditions: B-cell Chronic Lymphocytic Leukemia
Refractory Chronic Lymphocytic Leukemia

Interventions: Drug: fludarabine phosphate
Biological: rituximab
Biological: bevacizumab
Other: laboratory biomarker analysis
Other: flow cytometry
Genetic: polymerase chain reaction
Genetic: fluorescence in situ hybridization